Exploring the Future of Cannabinoid & Psychedelic Therapies with Joel Latham of Incannex Healthcare

In this episode of the Xtalks Life Science Podcast, Senior Life Science Journalist Ayesha Rashid speaks with Joel Latham, CEO, president and director of Incannex Healthcare, to discuss how the company is advancing cannabinoid and psychedelic therapies for chronic conditions like sleep apnea, rheumatoid arthritis and anxiety disorders. Joel has more than 20 years of senior management and operations experience in both public and private sectors. Under Joel’s leadership, Incannex has advanced and prioritized multiple therapeutic candidates into clinical-stage development. Previously, he was the CEO and Managing Director of Incannex Australia, where he played a key role in the company’s growth and its successful transition to Nasdaq. Joel has also held senior leadership roles in corporate strategy and global market development at Mars Foods, Tabcorp and Philip Morris International. Listen now to learn about the cutting-edge developments in cannabinoid and psychedelic medicine. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured